Abstract
Nanostructured Lipid Carriers (NLCs) represent a promising advancement in the treatment of breast cancer, addressing the significant challenges posed by conventional chemotherapy, such as poor drug solubility, short half-lives, and high toxicity. This review delves into the potential of NLCs to overcome these limitations, highlighting their unique structure comprising a solid and lipid liquid core stabilized by surfactants. By examining diverse lipid blends used in the preparation of NLCs, the article emphasizes their suitability for targeted drug delivery. Various facets of NLC configuration, categorization, composition, and formulation approaches are systematically explored to provide a comprehensive understanding of their attributes. The findings reveal that NLCs possess a high capacity for lipophilic drugs and offer advantages over traditional lipid-based nanocarriers. The review underscores the pivotal role of NLCs in enhancing drug delivery efficiency for breast cancer therapy while minimizing systemic toxicity. Conclusively, this review positions NLCs as a key player in the evolution of drug delivery systems for breast cancer treatment, providing a detailed outlook on their transformative potential and contributing to a nuanced understanding of their significance in advancing the field of breast cancer treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
